Small molecule · Inhibitor of protein arginine methyltransferase 5 (PRMT5) · developed by BeOne Medicines
BGB-58067 is a methylthioadenosine (MTA)-selective small-molecule inhibitor of PRMT5, a type II protein arginine methyltransferase. It binds PRMT5 in the presence of MTA, reducing monomethylated and dimethylated arginine on histone and non-histone proteins, and is designed to act preferentially in MTAP-deleted cancer cells. It is studied in cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07712640 | Phase 1 | Healthy Volunteers | Recruiting | ONC |
| NCT07590102 | Phase 1 | Healthy Volunteers | Recruiting | ONC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy Volunteers
See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ONC catalysts and pipeline →